RxDoctor Payments DataLook up a doctor →

Gary Vanetsky, PA

Medical · Encinitas, CANPI 1417034489

Payments from drug & device makers

$22,759in general payments, 2019–2025

Across 566 payments — averaging $40.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Arcutis Biotherapeutics, Inc.$2K
  • Johnson & Johnson$2K
  • Pfizer$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • plus $11K from 30 others

What the payments were for

  • Consulting fees$2,1029%
  • Speaking & faculty fees$1,2005%
  • Travel & lodging$320%
  • Food & beverage$18,87283%
  • Education$5532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,759 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$428,142
Medicare patients
840
Services billed
8,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast17$118,420
Fluorouracil97$6,092
Clobetasol Propionate60$1,867
Ketoconazole141$1,780
Fluocinonide56$1,404
ValacyclovirValacyclovir Hcl41$1,291
Metronidazole19$908
Triamcinolone Acetonide143$877
Doxycycline Hyclate40$773
Tretinoin16$768
Minoxidil119$763
Betamethasone Dipropionate17$612
Fluconazole20$414
Imiquimod18$341
Ciclopirox17$334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$858$118,42017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.

Other medical in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →